BR112015002249A2 - composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo - Google Patents
composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduoInfo
- Publication number
- BR112015002249A2 BR112015002249A2 BR112015002249A BR112015002249A BR112015002249A2 BR 112015002249 A2 BR112015002249 A2 BR 112015002249A2 BR 112015002249 A BR112015002249 A BR 112015002249A BR 112015002249 A BR112015002249 A BR 112015002249A BR 112015002249 A2 BR112015002249 A2 BR 112015002249A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- stereoisomer
- mammal
- treating
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Abstract
resumo composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo” a presente invenção fornece n-alquil 2-(dissubstituída)alquiniladenosina-5'-uronamidas e derivados das mesmas e composições farmacêuticas que contêm as mesmas que são agonistas seletivos de receptores de adenosina a2a (ars). esses compostos e composições são úteis como agentes farmacêuticos. 1/1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678605P | 2012-08-01 | 2012-08-01 | |
US201361787188P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/053053 WO2014022577A1 (en) | 2012-08-01 | 2013-07-31 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015002249A2 true BR112015002249A2 (pt) | 2017-07-04 |
Family
ID=50025663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015002249A BR112015002249A2 (pt) | 2012-08-01 | 2013-07-31 | composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo |
Country Status (15)
Country | Link |
---|---|
US (1) | US9067963B2 (pt) |
EP (1) | EP2879683B1 (pt) |
JP (1) | JP6545618B2 (pt) |
KR (1) | KR20150036767A (pt) |
CN (1) | CN104582709A (pt) |
AU (1) | AU2013296420B2 (pt) |
BR (1) | BR112015002249A2 (pt) |
CA (1) | CA2880040A1 (pt) |
EA (1) | EA027174B1 (pt) |
IL (1) | IL236986A (pt) |
IN (1) | IN2015DN00538A (pt) |
MX (1) | MX367879B (pt) |
NZ (1) | NZ703992A (pt) |
WO (1) | WO2014022577A1 (pt) |
ZA (1) | ZA201501350B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1888548B1 (en) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
US9822141B2 (en) * | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
RU2676694C9 (ru) | 2013-01-23 | 2019-06-25 | Альдейра Терапьютикс, Инк. | Заболевания, связанные с токсичным альдегидом, и их лечение |
JP6947406B2 (ja) | 2015-08-21 | 2021-10-13 | アルデイラ セラピューティクス, インコーポレイテッド | 重水素化化合物およびその使用 |
AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
EP3596040B1 (en) | 2017-03-16 | 2023-10-11 | Aldeyra Therapeutics, Inc. | Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof |
MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
WO2020253866A1 (zh) * | 2019-06-21 | 2020-12-24 | 中国人民解放军军事科学院军事医学研究院 | 腺苷类化合物、其可药用盐或其立体异构体及用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
JPS6299395A (ja) | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2−アルキニルアデノシンおよび抗高血圧剤 |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JPH02104783A (ja) * | 1988-10-11 | 1990-04-17 | Kanai Hiroyuki | スチールコードおよびタイヤ |
EP0444196B1 (en) | 1988-11-15 | 1994-06-08 | Yamasa Shoyu Kabushiki Kaisha | Agent for treatment and prophylaxis of ischemic disease of heart or brain |
KR920700218A (ko) | 1989-06-20 | 1992-02-19 | 원본미기재 | 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체 |
US5189027A (en) | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
JP3025557B2 (ja) * | 1991-06-28 | 2000-03-27 | ヤマサ醤油株式会社 | 2‐アルキニルアデノシン誘導体 |
IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
JP2002173427A (ja) * | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | 眼疾患治療用医薬組成物 |
US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
MXPA02009258A (es) | 2000-03-23 | 2005-04-19 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1. |
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
EP1537135B1 (en) | 2002-09-09 | 2009-11-25 | Cv Therapeutics, Inc. | Adenosine a3 receptor agonists |
NZ585697A (en) | 2004-08-02 | 2011-12-22 | Univ Virginia Patent Found | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
ATE500263T1 (de) * | 2006-06-27 | 2011-03-15 | Cbt Dev Ltd | Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten |
US20080312160A1 (en) | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
JP5349461B2 (ja) | 2007-05-17 | 2013-11-20 | ギリアード・パロ・アルト・インコーポレイテッド | A2a−アデノシン受容体アゴニストおよびその多形体を調製するための方法 |
US8293720B2 (en) | 2007-12-20 | 2012-10-23 | Dogwood Pharmaceuticals, Inc. | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
JP2012532140A (ja) * | 2009-06-30 | 2012-12-13 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | A2ar作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体 |
-
2013
- 2013-07-31 US US13/956,111 patent/US9067963B2/en not_active Expired - Fee Related
- 2013-07-31 AU AU2013296420A patent/AU2013296420B2/en not_active Ceased
- 2013-07-31 EA EA201590205A patent/EA027174B1/ru not_active IP Right Cessation
- 2013-07-31 CA CA2880040A patent/CA2880040A1/en not_active Abandoned
- 2013-07-31 MX MX2015001370A patent/MX367879B/es active IP Right Grant
- 2013-07-31 BR BR112015002249A patent/BR112015002249A2/pt not_active Application Discontinuation
- 2013-07-31 WO PCT/US2013/053053 patent/WO2014022577A1/en active Application Filing
- 2013-07-31 NZ NZ703992A patent/NZ703992A/en not_active IP Right Cessation
- 2013-07-31 EP EP13825985.8A patent/EP2879683B1/en active Active
- 2013-07-31 IN IN538DEN2015 patent/IN2015DN00538A/en unknown
- 2013-07-31 JP JP2015525562A patent/JP6545618B2/ja not_active Expired - Fee Related
- 2013-07-31 CN CN201380043401.9A patent/CN104582709A/zh active Pending
- 2013-07-31 KR KR20157004901A patent/KR20150036767A/ko not_active Application Discontinuation
-
2015
- 2015-01-29 IL IL236986A patent/IL236986A/en active IP Right Grant
- 2015-02-27 ZA ZA2015/01350A patent/ZA201501350B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201590205A1 (ru) | 2015-06-30 |
AU2013296420B2 (en) | 2017-12-07 |
AU2013296420A1 (en) | 2015-02-12 |
CN104582709A (zh) | 2015-04-29 |
EP2879683A1 (en) | 2015-06-10 |
KR20150036767A (ko) | 2015-04-07 |
US20140037538A1 (en) | 2014-02-06 |
JP6545618B2 (ja) | 2019-07-17 |
MX367879B (es) | 2019-09-10 |
EA027174B1 (ru) | 2017-06-30 |
IN2015DN00538A (pt) | 2015-06-26 |
EP2879683A4 (en) | 2016-04-20 |
NZ703992A (en) | 2018-04-27 |
US9067963B2 (en) | 2015-06-30 |
ZA201501350B (en) | 2016-12-21 |
JP2015524440A (ja) | 2015-08-24 |
WO2014022577A1 (en) | 2014-02-06 |
MX2015001370A (es) | 2016-04-26 |
IL236986A (en) | 2017-06-29 |
EP2879683B1 (en) | 2020-01-22 |
CA2880040A1 (en) | 2014-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015002249A2 (pt) | composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo | |
BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
EA201891509A1 (ru) | Способы лечения рака | |
CY1120159T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
BR112015007698A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
MX362442B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
BR112015016585A2 (pt) | Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos | |
BR112016029582A2 (pt) | derivados de exendina-4 como agonistas de receptor de glucagon seletivos | |
WO2015054500A3 (en) | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines | |
CL2015002402A1 (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3. | |
UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
WO2007098474A8 (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists | |
BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
BR112016002459A2 (pt) | Derivados de benzimidazolil-metil ureia como agonistas receptores de alx | |
CL2011000237A1 (es) | Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico. | |
BR112020012712A8 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc | |
MX369694B (es) | Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t). | |
UY35199A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3 | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
BR112013004192A2 (pt) | tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante | |
CL2015001419A1 (es) | Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor. | |
NZ721493A (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
CL2008002316A1 (es) | Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer. | |
UY34436A (es) | Metodo de control del peso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B07E | Notice of approval relating to section 229 industrial property law | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |